Blog Post

November 16, 2021

MPO Data Presented at ACR 2021

Myeloperoxidase activity in individuals with Anti-neutrophil cytoplasmic antibodies (ANCA) can be inhibited by RLS-0071

At the 2021 Annual Conference of Rheumatology (ACR), Dr. Parvathi Kumar, ReAlta’s Associate Director of Early Clinical Development, presented data demonstrating that lead compound RLS-0071 inhibits myeloperoxidase activity in individuals with anti-neutrophil cytoplasmic antibodies (ANCA).

RLS-0071 is a PEGylated peptide which inhibits MPO activity in animal models and ex vivo and also inhibits neutrophil mediated NETosis in vitro and in vivo.

ReAlta conducted a pilot study measuring MPO activity in patient samples acquired commercially from a biorepository. AI (Antibody Index) units were available for each sample which represents a manufacturer specific composite score of anti-MPO, anti-PR3 and anti-GBM antibody titers.

In this pilot study, ReAlta’s researchers found that plasma from ANCA patients demonstrated a wide range of MPO activity and the AI unit appears to generally trend with plasma MPO activity. We also demonstrated that RLS-0071 inhibits MPO activity in plasma acquired from individuals with ANCA-associated pathophysiology. Future studies will focus on elucidating relationships between MPO activity, MPO quantity, free plasma DNA as a surrogate measurement of NETs and anti-MPO titers.

More information about the American College of Rheumatology can be found at this link.

MORE BLOGS & INDUSTRY UPDATES

Oct 26, 2020

Facility Tours

Dr. Neel Krishna and Dr. Katherine LaVallee, DVM did an outstanding job leading tours of our lab and offices last...

Read More
Oct 21, 2020

New ReAlta Headquarters

We want to thank Rep. Elaine Luria and Norfolk Mayor Dr. Kenneth Alexander for helping us celebrate the official opening...

Read More
Apr 30, 2021

HIE Awareness Month

ReAlta Life Sciences is officially part of Team Hope! We are extending our gratitude to the Hope for HIE team...

Read More